Adient Medical, Inc.
Our mission is the development of absorbable medical devices with the premise that implants should be safe and effective during their useful lifetime, and then simply vanish without intervention, alleviating costly removal procedures and downstream complications. The company was founded in 2012 by Mitch Eggers, an engineer and inventor, who learned of the pitfalls of conventional metallic devices such as intravascular stents and filters while attending medical school at Baylor College of Medicine. He built a cardiovascular simulator in his garage that mimicked human physiology to test a plethora of absorbable polymers for potential device application. A class of polymers was identified that retained strength for months under the rigor of the cardiovascular system before breaking down into mere carbon dioxide and water.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Nationally (across the country)
Our Story
Mitch then designed several intravascular filters and stents from braiding the polymers and successfully tested them in the simulator that led to the top award in surgery and bioengineering research at the annual American Medical Association conference.
Sharing his discovery with a cycling friend on a weekend ride through the Texas countryside led to a meeting with the chairman of Interventional Radiology at the University of Texas MD Anderson Cancer Center. The late Michael Wallace MD helped form the intradisciplinary team that included interventional radiologist Steven Huang MD, who together with Mitch, first demonstrated in 2013 the interception of a blood clot that subsequently resorbed in an absorbable intravascular filter thereby preventing pulmonary embolism and establishing feasibility of the concept.
Medical Devices that Automatically Vanish
Indication for Use
The Adient Absorbable Vena Cava Filter is intended for the temporary prevention of pulmonary embolism in patients with transient high risk for venous thromboembolism (DVT and/or PE) with or without venous thromboembolic disease and as an enhancement to pharmaceutical anticoagulation and mechanical prophylaxis. The Adient Absorbable Vena Cava Filter does not require retrieval.
Patients requiring temporary prevention of potential pulmonary embolism include major trauma, major orthopedic procedures such as total knee replacement, and patients in surgical ICU. Here the likelihood of PE is substantially higher than the general population and would benefit from an absorbable filter.
Note: The Adient Absorbable Vena Cava Filter is not commercially available. Food and Drug Administration (FDA) approval requires successful completion of the US clinical trial.